Biotechnology

Wednesday Oct 04, 2023 - 9:47 am

InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces Participation at CPHI Barcelona 2023, Other Upcoming Events

Scinai Immunotherapeutics (NASDAQ: SCNI) today announced that it will showcase its CDMO services at CPHI Barcelona, one of the international pharmaceutical industry’s premier trade shows, taking place Oct. 24 to 26. Scinai’s CDMO offers upstream and downstream process development and scale-up for protein-based drugs, analytical method development, and cGMP manufacturing including aseptic filling to biopharmaceutical and biotech clients. According to the announcement, several members of…

Monday Oct 02, 2023 - 12:34 pm

InvestorNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB) CEO Releases Shareholder Letter Regarding Agreement to Combine with Leading AI Company

Renovaro BioSciences (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, is sharing a shareholder letter from Renovaro CEO Mark R. Dybul, MD. In the letter, Dybul provides information about the definitive agreement the company recently signed with artificial intelligence company GEDiCube. In the letter, Dybul noted that the two companies…

Friday Sep 29, 2023 - 3:46 pm

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases FY 2023 Report, Shares Corporate Update

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, is reporting on the financial results for its fiscal year 2023, the period ending June 30, 2023. In addition, the company provided a status update on its pharmaceutical drug-development programs as well as the commercial segment for BayMedica LLC, its wholly owned subsidiary. Highlights of…

Thursday Sep 28, 2023 - 10:12 am

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Investigational Drug Focus of Study Published in Peer-Reviewed Journal

Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis, announced the publication of a scientific paper. The paper, which was published in the “Small” journal, describes the catalytic mechanism of action of CLNN’s investigational drug CNM-Au8(R).…

Wednesday Sep 27, 2023 - 11:51 am

InvestorNewsBreaks – CSurgeries, Sheltowee Network Partner to Relaunch Platform, Revolutionize Surgical Training

CSurgeries, a top-tier online surgical video journal, is collaborating with Sheltowee Network, a leading innovation commercialization company. According to the announcement, the two companies will work together to make high-quality, peer-reviewed surgical content more accessible for medical professionals and students around the world. CSurgeries is redesigning its platform to add new features as well as an invaluable library of surgical videos; the company is also…

Tuesday Sep 26, 2023 - 12:00 pm

InvestorNewsBreaks – SOHM, Inc. (SHMN) Announces Acquisition of World-Class Gene-Editing Platform

SOHM (OTC: SHMN), a pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, today announced it has acquired ABBIE, a world-class gene-editing platform that can deliver genetic payloads using non-viral vectors. Through this acquisition, SOHM is well-positioned as a competitive player in the $5.3 billion gene-editing market in 2023, which is expected to grow to $10.8 billion by 2028…

Tuesday Sep 26, 2023 - 11:54 am

InvestorNewsBreaks – Safety Shot Holdings Inc. (NASDAQ: SHOT) Announces Board Appointment of the Honorable Jack Brewer, M.Ed.

Safety Shot (NASDAQ: SHOT) today announced that Jack Brewer, M.Ed. has joined the company’s advisory board. Brewer is an ordained minister who possesses a unique combination of expertise in the fields of global economic development, sports and finance through his roles as a successful entrepreneur, executive producer, news contributor and humanitarian. He currently serves as CEO and portfolio manager of The Brewer Group Inc., White…

Tuesday Sep 26, 2023 - 11:03 am

InvestorNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Names Experienced Leaders to New Senior Management Positions

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (“VECG”) platform for patient use at home allowing for the creation of rich data for AI, has appointed two new team leaders. The company announced that Richa Gujarati will serve as senior vice president over product, and Pooja Chatterjee will be vice president over clinical. The two…

Friday Sep 22, 2023 - 2:24 pm

InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Making Significant Strides to Advance Cellular Therapy Programs

Longeveron (NASDAQ: LGVN) is a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-related Frailty. “The company is guided by the mission to advance cell-based product candidates into pivotal phase 3 trials, with the goal of attaining regulatory approvals and subsequently commercializing the product. Longeveron has so far made significant strides in…

Friday Sep 22, 2023 - 1:59 pm

InvestorNewsBreaks – RVL Pharmaceuticals plc (NASDAQ: RVLP) Anticipating Growing Demand for UPNEEQ(R)

RVL Pharmaceuticals (NASDAQ: RVLP) is a a specialty pharmaceutical company whose near-term focus is to continue the rollout of UPNEEQ(R) into the medical aesthetics market through its dedicated sales force. “UPNEEQ(R) is the first non-surgical treatment option approved by the U.S. Food and Drug Administration (‘FDA’) for acquired blepharoptosis… UPNEEQ(R), the first and only FDA-approved eye drop for low-lying eyelids, fits into the non-invasive medical…

Friday Sep 22, 2023 - 1:46 pm

InvestorNewsBreaks – Why PaxMedica Inc. (NASDAQ: PXMD) Is ‘One to Watch’

PaxMedica (NASDAQ: PXMD) is a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic therapies (“APTs”) for the treatment of autism spectrum disorder (“ASD”) and other serious conditions with intractable neurologic symptoms. “The company’s lead programs are focused on ASD, for which there are currently no approved pharmacologic treatments that target its cause and symptoms. Currently used treatments only address the symptoms of…

Friday Sep 22, 2023 - 1:37 pm

InvestorNewsBreaks – SOHM Inc. (SHMN) Expands Team to Direct Global Growth Strategy

SOHM (OTC: SHMN) is a pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories. “SOHM is strengthening its governing team with the addition of two experienced visionaries committed to helping the company’s growth in the pharmaceutical, nutraceutical and cosmeceutical marketplace… The new officers are expected to help direct SOHM’s global growth strategy as the company continues to develop and…

Friday Sep 22, 2023 - 10:29 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Featured in InvestmentPitch Media Video

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a company building a portfolio of innovative assets and biotech solutions, was featured in an InvestmentPitch media video that discusses continued development of UNBUZZD(TM), the company’s new rapid detox drink. UNBUZZD(TM) is a proprietary formulation of natural ingredients, vitamins and minerals to help relieve the effects of alcohol consumption, such as inebriation, and restoring normal lifestyle. Kevin…

Thursday Sep 21, 2023 - 3:11 pm

InvestorNewsBreaks – IBN’s BioMedWire Highlights NanoVibronix Inc.’s (NASDAQ: NAOV) $5M Private Placement

IBN, a multifaceted financial news and publishing company for private and public entities, has announced, through its biotech and biomed brand BioMedWire, the recent private placement offering for NanoVibronix (NASDAQ: NAOV), a medical device company that produces the UroShield(R), PainShield(R) and WoundShield(R) Surface Acoustic Wave (“SAW”) Portable Ultrasonic Therapeutic Devices. NanoVibronix in late August entered into definitive agreements for the purchase and sale of an…

Wednesday Sep 20, 2023 - 11:54 am

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Building Protection and Powerful IP Portfolio for Its Diabetes Gene Therapy Program

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, recently announced its entry into an exclusive license agreement related to a particular gene therapy for both type 1 and type 2 diabetes. “Specifically, the announcement involves a worldwide exclusive license to a patent application and related technology, and a worldwide non-exclusive license to use certain…

Wednesday Sep 20, 2023 - 9:15 am

InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Closes on $1.33M Registered Direct Offering

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases, has closed on a registered direct offering of 1,146,552 of the company’s American Depositary Shares (“ADSs”). According to the announcement, each ADS represented four hundred ordinary shares offered at $1.16 per ADS (or ADS equivalent). The announcement…

Friday Sep 15, 2023 - 12:54 pm

InvestorNewsBreaks – Why Renovaro BioSciences Inc. (NASDAQ: RENB) Is ‘One to Watch’

Renovaro BioSciences (NASDAQ: RENB), (formerly Enochian BioSciences Inc.), is an advanced, pre-clinical biotechnology firm in cell, gene and immunotherapy. “Renovaro aims to unlock potentially long-term or life-long cancer remission in some of the deadliest cancers, as well as to potentially treat or cure serious infectious diseases… The oncology platform is now at the forefront of Renovaro’s development activities. While Renovaro’s current efforts focus primarily on…

Friday Sep 15, 2023 - 12:26 pm

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Looks Forward to Acclaim-3 Trial on Heels of Receipt of FDA FTD and ODD Designations

Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes. The company recently announced that the United States Food and Drug Administration (“FDA”) had granted Orphan Drug Designation (“ODD”) to its lead drug candidate, REQORSA(R) Immunogene Therapy (quratusugene ozeplasmid), for the treatment of small cell lung cancer (“SCLC”). The receipt of the ODD followed the…

Friday Sep 15, 2023 - 12:12 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Optimistic Berubicin May Provide Much-Needed Benefit for GBM Patients

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biotechnology company specializing in the development of novel treatments with a focus on brain cancer, glioblastoma (“GBM”) and neuro-oncology, recently presented updated safety results from its potentially pivotal clinical study on GBM treatment through its lead drug candidate, Berubicin. “Most notably, this novel anthracycline demonstrated its capability to be a safe and innovative potential treatment option for GBM, having…

Friday Sep 15, 2023 - 10:02 am

InvestorNewsBreaks – Safety Shot (NASDAQ: SHOT) Rebrands with New Name, Ticker to Focus on New Business

Safety Shot (NASDAQ: SHOT), formerly known as Jupiter Wellness, has announced that effective today it has changed its name to Safety Shot; its ticker will also change to SHOT. The changes come after the company acquired Safety Shot, the first patented beverage that helps a person feel better faster by reducing blood alcohol content while also boosting clarity. The new beverage is currently being produced in the…

Friday Sep 15, 2023 - 9:55 am

InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces $1.33M Registered Direct

Scinai Immunotherapeutics (NASDAQ: SCNI) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products primarily for the treatment of autoimmune and infectious diseases. The company today announced its entry into a definitive agreement for the purchase and sale of 1,146,552 of the company’s American Depositary Shares (“ADSs”) (or ADS equivalents), each ADS representing 400 ordinary shares, at a…

Thursday Sep 14, 2023 - 1:47 pm

InvestorNewsBreaks – Lucy Scientific Discovery Inc. (NASDAQ: LSDI) Collaborates to Unlock the Value of Brands Through Strategic Acquisitions

Lucy Scientific Discovery (NASDAQ: LSDI), a publicly traded company focused on the development, sale, delivery, and manufacturing of psychotropic products, recently announced the acquisition of BlueSky Wellness Inc., along with its portfolio of brands, which adds psychotropic products to its catalog and expands its footprint into the global wellness market. BlueSky wellness-focused ecommerce brands include Keoni, Keoni Sport, Blush Wellness and AMMA Healing, which, in…

Wednesday Sep 13, 2023 - 10:12 am

InvestorNewsBreaks – Lucy Scientific Discovery Inc. (NASDAQ: LSDI) Announces Acquisition of BlueSky Wellness, Expands Footprint in Global Wellness Market

Lucy Scientific Discovery (NASDAQ: LSDI), a publicly traded company focused on the development, sale, delivery and manufacturing of psychotropic products, is acquiring BlueSky Wellness Inc. and the BlueSky portfolio of brands. According to the announcement, the acquisition adds psychotropic products to the company’s catalog, enabling LSDI to expand its footprint in the global wellness market. BlueSky Wellness brands include Keoni, Keoni Sport, Blush Wellness and…

Wednesday Sep 13, 2023 - 10:06 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Coverage Initiated by Singular Research

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders. The company today announced that Singular Research has initiated analyst coverage on FSD Pharma. The company has not paid for the research report prepared by Singular Research, and all reports on FSD Pharma…

Tuesday Sep 12, 2023 - 10:00 am

InvestorNewsBreaks – Lucy Scientific Discovery Inc. (NASDAQ: LSDI) to Acquire BlueSky Wellness Inc. in All-Stock Transaction

Lucy Scientific Discovery (NASDAQ: LSDI) is the leader in the psychotropic industry, which recently celebrated the acquisition of the intellectual property of High Times, the most iconic brand in the cannabis industry. Today the company announced an agreement to acquire BlueSky Wellness Inc. and its portfolio of brands, expanding Lucy’s footprint into the growing global wellness category by adding psychotropic products to its capabilities. BlueSky…

Monday Sep 11, 2023 - 2:03 pm

InvestorNewsBreaks – SOHM Inc. (SHMN) Names Seasoned Veteran as VP of Quality

SOHM (OTC: SHMN), a pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, has appointment a new vice president of quality. The company announced that Wm. Dewey Rushing will be serving as SOHM vice president for quality. Rushing has been serving on the company’s advisory board member and that experience combined with his impressive background in management and leadership…

Monday Sep 11, 2023 - 11:00 am

InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces Participation in H.C. Wainwright, LSX USA Congress 2023 and Upcoming Conferences

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company formerly known as BiondVax Pharmaceuticals Ltd., today announced that its CEO Amir Reichman and Chairman of the Board Mark Germain will be attending the H.C. Wainwright 25th Annual Global Investment Conference in New York today and tomorrow (Sept. 11 and 12) and the LSX USA Congress 2023 in Boston this Wednesday and Thursday (Sept. 13 and 14). Investors…

Monday Sep 11, 2023 - 10:26 am

InvestorNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) CEO Releases Stockholder Letter

Longeveron (NASDAQ: LGVN; LGVNR), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, has issued a letter to its stockholders. The letter, from CEO Wa’el Hashad, contains a business update regarding the company’s development of its lead investigational product, Lomecel-B(TM), as well as steps taken to strengthen the board…

Friday Sep 08, 2023 - 12:23 pm

InvestorNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) ‘Strategically Important’ Patent Grants Protection in One of World’s Leading Oral Nicotine Markets

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently celebrated the receipt of U.S. patent #11,700,875, titled “Compositions and Methods For Sublingual Delivery of Nicotine.” The patent covers various forms and sources of nicotine, including nicotine benzoate, nicotine polacrilex, nicotine citrate, nicotine detartrate, and many others, for use in sublingual delivery formats like oral pouches. “The new U.S. patent is remarkable…

Friday Sep 08, 2023 - 11:58 am

InvestorNewsBreaks – Lucy Scientific Discovery Inc. (NASDAQ: LSDI) Strengthening Position in Projected $51B Global Cannabis Market

Lucy Scientific Discovery (NASDAQ: LSDI) is featured in a recent FinancialNewsMedia (“FNM”) Editorial. The editorial provides an overview of LSDI’s position in a global cannabis market projected to hit $51 billion this year. According to the press release, the global cannabis market has seen consistent growth year after year, with increasing legalization of cannabis fueling that growth. The release notes that a recent Statista report…

Thursday Sep 07, 2023 - 1:29 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces 200-Patient Enrollment Milestone in Potentially Pivotal Berubicin Study

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced enrollment of 200 of the expected 243 patients in the company’s ongoing potentially pivotal study evaluating Berubicin for the treatment of recurrent Glioblastoma Multiforme (“GBM”), an aggressive and incurable form of brain cancer. “As we have noted…

Thursday Sep 07, 2023 - 1:22 pm

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Present at H.C. Wainwright 25th Annual Global Investment Conference

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing, and commercialization of rare cannabinoids and cannabinoid analogs, today announced its participation in the H.C. Wainwright Global Investment Conference, which is taking place Sept. 11-13, 2023, in New York City. The on-demand presentation by InMed’s CEO Eric A. Adams will be available beginning at 7 a.m. ET on Sept. 11 via webcast, and…

Thursday Sep 07, 2023 - 12:02 pm

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Upcoming H.C. Wainwright Conference

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that its CFO Ryan Confer will be providing an overview of the company's pioneering gene therapies for cancer and diabetes at the upcoming H.C. Wainwright 25th Annual Global Investment Conference. Confer’s presentation is scheduled to begin at 3:00 p.m. ET on Wednesday, Sep. 13,…

Thursday Sep 07, 2023 - 11:40 am

InvestorNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Announces ELPIS 1 Trial Data Accepted for AHA Presentation, IBN Partnership

Longeveron (NASDAQ: LGVN; LGVNR), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, will be participating at the American Heart Association Scientific Sessions. The company announced that an abstract outlining long-term survival data from its ELPIS 1 trial of Lomecel-B(TM) for patients with HLHS has been accepted for presentation as a…

Thursday Sep 07, 2023 - 11:04 am

InvestorNewsBreaks – Lucy Scientific Discovery Inc. (NASDAQ: LSDI) Acquires High Times Intellectual Property, Featured in Financial News Media Article

Lucy Scientific Discovery (NASDAQ: LSDI) today announced the acquisition of the intellectual property (“IP”) of High Times, an iconic brand in the cannabis industry. In addition to the Hightimes.com domain, the transaction also includes the trademarks for the Cannabis Cup and 420.com brands and their respective domain names. In exchange, High Times will receive a 19.9% stake in Lucy's outstanding stock as well as performance-based…

Wednesday Sep 06, 2023 - 3:03 pm

InvestorNewsBreaks – Why RVL Pharmaceuticals plc (NASDAQ: RVLP) Is ‘One to Watch’

RVL Pharmaceuticals (NASDAQ: RVLP) is a specialty pharmaceutical company focusing on the commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution), 0.1%, available by prescription for the treatment of acquired blepharoptosis (low-lying eyelid(s)) in adults. “UPNEEQ(R) (‘RVL-1201’) is the first non-surgical treatment option approved by the U.S. Food and Drug Administration (‘FDA’) for acquired blepharoptosis. The company received FDA approval in July 2020 and launched UPNEEQ(R) in…

Wednesday Sep 06, 2023 - 12:34 pm

InvestorNewsBreaks – HippoFi Inc. (ORHB) Collaborates to Bring ‘Innovative Technology to the Forefront of Spinal Treatments’

HippoFi (OTC: ORHB), a leading health care technology company and authority in spinal biologics, has announced a partnership with global medical technology leader Zimmer Biomet, aiming to redefine the spinal biologics landscape. According to the announcement, the collaboration will harness the combined expertise of both companies to introduce a novel synthetic biomaterial for bone growth, set for a 2024 launch under HippoFi’s subsidiary, PUR Biologics.…

Wednesday Sep 06, 2023 - 10:33 am

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Rebrands as Scinai Immunotherapeutics Ltd.

BiondVax (NASDAQ: BVXV), a biotechnology company, today announced a change of its corporate name to Scinai Immunotherapeutics, which will debut on the Nasdaq under a new symbol, SCNI, on Sept. 7, 2023. In the past two years, the company has revamped its senior management team and pharmaceuticals development programs and recently announced its expansion into the CDMO business under the banner Scinai Bioservices. The new…

Tuesday Sep 05, 2023 - 10:44 am

InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) to Present at Upcoming H.C. Wainwright Global Investment Conference

Longeveron (NASDAQ: LGVN, LGVNR), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-related Frailty, today announced that its management will be participating in the 25th Annual H.C. Wainwright Global Investment Conference. The event is slated to take place in New York City from Sept. 11-13, 2023. Longeveron’s CEO Wa’el…

Tuesday Sep 05, 2023 - 10:33 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation at Upcoming H.C. Wainwright Global Investment Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be presenting at the 25th annual H.C. Wainwright Global Investment Conference. The conference is slated for Sept. 11–13, 2023, in New York City. According to the announcement, CNS Pharmaceuticals CEO Climaco is scheduled to present during the two-day…

InvestorNewsBreaks

NewsBreak Category: Biotechnology

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions